Athira Pharma, Inc. (NASDAQ:LONA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Athira Pharma, Inc. (NASDAQ:LONA) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $17.3333.

LONA has been the topic of a number of research analyst reports. Piper Sandler initiated coverage on shares of Athira Pharma in a research report on Wednesday, May 27th. They set an “overweight” rating and a $20.00 price objective on the stock. Wall Street Zen upgraded shares of Athira Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a report on Friday, August 7th. Citizens Jmp decreased their price target on shares of Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating on the stock in a research report on Monday, August 17th. Finally, Mizuho dropped their price target on shares of Athira Pharma from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 19th.

Institutional Investors Weigh In On Athira Pharma

Institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC lifted its position in shares of Athira Pharma by 244.1% in the fourth quarter. Perceptive Advisors LLC now owns 1,859,322 shares of the company’s stock valued at $14,075,000 after acquiring an additional 1,319,026 shares in the last quarter. Commodore Capital LP purchased a new stake in shares of Athira Pharma during the fourth quarter worth about $3,515,000. Spruce Street Capital LP purchased a new stake in shares of Athira Pharma during the fourth quarter worth about $2,980,000. ADAR1 Capital Management LLC bought a new stake in Athira Pharma during the 4th quarter valued at approximately $2,891,000. Finally, Millennium Management LLC bought a new stake in Athira Pharma during the 4th quarter valued at approximately $2,456,000. Hedge funds and other institutional investors own 57.12% of the company’s stock.

Athira Pharma Price Performance

NASDAQ LONA opened at $6.86 on Friday. The business’s 50-day moving average is $7.93 and its 200 day moving average is $8.62. Athira Pharma has a 1 year low of $3.52 and a 1 year high of $14.21. The stock has a market capitalization of $64.42 million, a PE ratio of -1.63 and a beta of 2.05.

Athira Pharma (NASDAQ:LONA) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.20). As a group, equities research analysts anticipate that Athira Pharma will post -2.67 earnings per share for the current year.

Athira Pharma Company Profile

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.